top of page

Off-Target Effects Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

blonca9
Jun 30
1 min read

Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make targets attractive, and how the industry has changed over time during the course of his career. Plus, what attracted him to Jefferies.

Recent Posts

See All

Off-Target Effects Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

Off-Target Effects Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

Off-Target Effects Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate